 Warfarin
"Warfarin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
| Descriptor ID |
D014859
|
| MeSH Number(s) |
D03.438.150.446.520.914 D03.830.219.446.520.914
|
| Concept/Terms |
Warfarin- Warfarin
- 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
Coumadine- Coumadine
- Bailly Brand of Warfarin Sodium
Warfant- Warfant
- Antigen Brand of Warfarin Sodium
Coumadin- Coumadin
- Goldshield Brand of Warfarin Sodium
- Marevan
- Boots Brand of Warfarin Sodium
- Bristol-Myers Squibb Brand of Warfarin Sodium
Aldocumar- Aldocumar
- Aldo Brand of Warfarin Sodium
Tedicumar- Tedicumar
- Estedi Brand of Warfarin Sodium
|
Below are MeSH descriptors whose meaning is more general than "Warfarin".
Below are MeSH descriptors whose meaning is more specific than "Warfarin".
This graph shows the total number of publications written about "Warfarin" by people in this website by year, and whether "Warfarin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 | | 2003 | 1 | 1 | 2 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 2 | 2 | 4 | | 2007 | 1 | 0 | 1 | | 2008 | 1 | 2 | 3 | | 2009 | 1 | 2 | 3 | | 2010 | 1 | 1 | 2 | | 2011 | 1 | 1 | 2 | | 2012 | 4 | 0 | 4 | | 2013 | 1 | 0 | 1 | | 2014 | 2 | 1 | 3 | | 2015 | 2 | 2 | 4 | | 2016 | 1 | 2 | 3 | | 2017 | 4 | 0 | 4 | | 2018 | 1 | 1 | 2 | | 2019 | 3 | 1 | 4 | | 2020 | 1 | 0 | 1 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Warfarin" by people in Profiles.
-
Yaghi S, Shu L, Bakradze E, Salehi Omran S, Giles JA, Amar JY, Henninger N, Elnazeir M, Liberman AL, Moncrieffe K, Lu J, Sharma R, Cheng Y, Zubair AS, Simpkins AN, Li GT, Kung JC, Perez D, Heldner M, Scutelnic A, Seiffge D, Siepen B, Rothstein A, Khazaal O, Do D, Kasab SA, Rahman LA, Mistry EA, Kerrigan D, Lafever H, Nguyen TN, Klein P, Aparicio H, Frontera J, Kuohn L, Agarwal S, Stretz C, Kala N, El Jamal S, Chang A, Cutting S, Xiao H, de Havenon A, Muddasani V, Wu T, Wilson D, Nouh A, Asad SD, Qureshi A, Moore J, Khatri P, Aziz Y, Casteigne B, Khan M, Cheng Y, Mac Grory B, Weiss M, Ryan D, Vedovati MC, Paciaroni M, Siegler JE, Kamen S, Yu S, Leon Guerrero CR, Atallah E, De Marchis GM, Brehm A, Dittrich T, Psychogios M, Alvarado-Dyer R, Kass-Hout T, Prabhakaran S, Honda T, Liebeskind DS, Furie K. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Stroke. 2022 03; 53(3):728-738.
-
Jansma B, Montgomery J, Dietrich S, Mixon MA, Peksa GD, Faine B. Emergent Warfarin Reversal With Fixed-Dose 4-Factor Prothrombin Complex Concentrate. Ann Pharmacother. 2020 11; 54(11):1090-1095.
-
Peksa GD, Mokszycki RK, Rech MA, Maynard B, Panos NG, Sweis RT, DeMott JM. Reversal of Warfarin-Associated Major Hemorrhage: Activated Prothrombin Complex Concentrate versus 4-Factor Prothrombin Complex Concentrate. Thromb Haemost. 2020 Feb; 120(2):207-215.
-
Manista GC, Batko BD, Sexton AC, Edmiston TA, Courtney PM, Hannon CP, Levine BR. Anticoagulation in Revision Total Joint Arthroplasty: A Retrospective Review of 1917 Cases. Orthopedics. 2019 Nov 01; 42(6):323-329.
-
Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Anderson JL, Li J, Rodriguez T, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple B, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dávila-Román V, Eby CS. Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial. JAMA. 2019 09 03; 322(9):834-842.
-
Feldman DN, Wang TY, Chen AY, Swaminathan RV, Kim LK, Wong SC, Minutello RM, Bergman G, Singh HS, Madias C. In-Hospital Bleeding Outcomes of Myocardial Infarction in the Era of Warfarin and Direct Oral Anticoagulants for Atrial Fibrillation in the United States: A Report From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry. J Am Heart Assoc. 2019 04 16; 8(8):e011606.
-
Benzon HT, Asher Y, Kendall MC, Vida L, McCarthy RJ, Green D. Clotting-Factor Concentrations 5 Days After Discontinuation of Warfarin. Reg Anesth Pain Med. 2018 Aug; 43(6):616-620.
-
Trohman RG, Sharma PS. Detecting and managing device leads inadvertently placed in the left ventricle. Cleve Clin J Med. 2018 Jan; 85(1):69-75.
-
Mangla A, Bjorklund JK, Kalra DK. An unusual echo after ventricular tachycardia ablation. Heart. 2018 02; 104(4):359-360.
-
Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodríguez T, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple BD, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dávila-Román V, Eby CS. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial. JAMA. 2017 09 26; 318(12):1115-1124.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|